Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma (SPL) signs an exploratory Dendrimer Drug Delivery (DEP) research agreement with US Biopharma company, Genentech
- Genetech has an initial focus on evaluating DEP, dendrimer-based drug conjugates
- Starpharma’s dendrimer-based drug delivery is being used to improve pharmaceuticals, reduce toxicities and enhance their performance
- The company also has a number of existing DEP partnerships including AstraZeneca, Merck & Co and Chase Sun
- Company shares are up 5.7 per cent at $1.21 at 10:40 am AEDT
Starpharma (SPL) has signed an exploratory Dendrimer Drug Delivery (DEP) research agreement with US Biopharma company, Genentech.
Genentech is a member of the Roche Group with an initial focus on evaluating DEP, dendrimer-based drug conjugates.
Starpharma’s dendrimer-based drug delivery is being used to improve pharmaceuticals, reduce toxicities and enhance their performance.
The company says the DEP platform has also shown reproducible advantages across a wide range of drug classes and can be utilised with both small molecule drugs, peptides and proteins.
Starpharma also has a number of existing DEP partnerships with leading international pharmaceutical companies for a variety of applications and diseases.
These companies include AstraZeneca, Merck & Co, Chase Sun and other disclosed partnerships.
Starpharma’s DEP technology has already yielded four clinical-stage products.
Company shares are up 5.7 per cent at $1.21 at 10:40 am AEDT.
